Dr. Haider Mahdi, MD
Claim this profileUniversity of Pittsburgh Cancer Institute (UPCI)
Studies Ovarian Cancer
Studies Relapse
14 reported clinical trials
24 drugs studied
Area of expertise
1Ovarian Cancer
Stage IV
BRCA1 positive
BRCA1 negative
2Relapse
Stage IV
HER2 positive
RB1 negative
Affiliated Hospitals
Clinical Trials Haider Mahdi, MD is currently running
ALX148 + Chemotherapy + Immunotherapy
for Ovarian Cancer
Immunotherapy with immune checkpoint inhibitors, including pembrolizumab, have emerged as a promising option in several solid cancers with durable effect and low toxicity profile. However, the benefit is limited to smaller subset of solid tumors. This trial involves the enhancement of current immune checkpoint-based immunotherapy with ALX148, an agent that inhibits CD47 (a trans-membrane protein that is highly expressed on the surface of many solid tumors as compared to normal cells).
Recruiting1 award Phase 214 criteria
E7777 + Pembrolizumab
for Ovarian Cancer
Epithelial ovarian cancer (OC) is the most lethal gynecologic cancer: nearly 22,000 women are diagnosed with OC in the US annually and 63% are expected to die from their disease. The 5-year overall survival rate is unacceptably low at 20-30%, with \> 50% of patients experiencing recurrence of their disease. Recurrent, platinum-resistant OC is characterized by a low response to chemotherapy (\<10-15%) and poor prognosis, with overall survival estimated to be \<12 months. Thus, there is an urgent need to identify novel therapies to improve outcomes for patients with recurrent, platinum resistant OC. The primary focus in this trial is targeting tumor associated immunosuppressive T-regs with E7777 combined with PD-1 inhibitor, pembrolizumab. This trial will enroll patients with solid tumors in the dose escalation portion and specified cohorts in the dose expansion portion. In the Phase I portion, 18-30 patients will be enrolled. In the dose expansion portion, approximately 40 patients (20 in each cohort) will be enrolled. Given the relatively poor prognosis and limited treatment options for these patients, this population is considered appropriate for trials of novel therapeutic candidates.
Recruiting1 award Phase 1 & 216 criteria
More about Haider Mahdi, MD
Clinical Trial Related1 year of experience running clinical trials · Led 14 trials as a Principal Investigator · 7 Active Clinical TrialsTreatments Haider Mahdi, MD has experience with
- ZEN003694
- Pembrolizumab
- Ipilimumab
- Nivolumab
- Neratinib
- Palbociclib
Breakdown of trials Haider Mahdi, MD has run
Ovarian Cancer
Relapse
Cancer
Solid Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Haider Mahdi, MD specialize in?
Haider Mahdi, MD focuses on Ovarian Cancer and Relapse. In particular, much of their work with Ovarian Cancer has involved Stage IV patients, or patients who are BRCA1 positive.
Is Haider Mahdi, MD currently recruiting for clinical trials?
Yes, Haider Mahdi, MD is currently recruiting for 7 clinical trials in Pittsburgh Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Haider Mahdi, MD has studied deeply?
Yes, Haider Mahdi, MD has studied treatments such as ZEN003694, Pembrolizumab, Ipilimumab.
What is the best way to schedule an appointment with Haider Mahdi, MD?
Apply for one of the trials that Haider Mahdi, MD is conducting.
What is the office address of Haider Mahdi, MD?
The office of Haider Mahdi, MD is located at: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania 15232 United States. This is the address for their practice at the University of Pittsburgh Cancer Institute (UPCI).
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.